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A variety of signals finely tune insulin secretion by
pancreatic b cells to prevent both hyper-and hypo-
glycemic states. Here, we show that post-transla-
tional regulation of the transcription factors ETV1,
ETV4, and ETV5 by the ubiquitin ligase COP1 (also
called RFWD2) in b cells is critical for insulin secre-
tion. Mice lacking COP1 in b cells developed dia-
betes due to insulin granule docking defects that
were fully rescued by genetic deletion of Etv1, Etv4,
and Etv5. Genes regulated by ETV1, ETV4, or ETV5
in the absence of mouse COP1 were enriched in hu-
man diabetes-associated genes, suggesting that
they also influence human b-cell pathophysiology.
In normal b cells, ETV4 was stabilized upon mem-
brane depolarization and limited insulin secretion un-
der hyperglycemic conditions. Collectively, our data
reveal that ETVs negatively regulate insulin secretion
for the maintenance of normoglycemia.INTRODUCTION
Inadequate insulin release in response to glucose is a hallmark in
the progression of type 2 diabetes. Initially thought of as a dis-
ease primarily driven by insulin resistance, it is now clear that
b-cell dysfunction and impaired insulin release are key contribu-
tors to the chronic hyperglycemia seen in type 2 diabetic
patients (Kahn, 1998, 2001; Weir and Bonner-Weir, 2004).
Secreted from pancreatic b cells in response to elevated
glucose load, insulin is the sole hormone able to reduce blood
glucose levels (Rorsman and Braun, 2013). While b cells activate
a number of mechanisms to increase insulin secretion in
response to elevated glucose (Prentki and Nolan, 2006), sus-
tained hyperglycemia or hyperkalemia elicits a dose-dependent
decrement in b-cell insulin secretion (Eizirik et al., 1992; Yama-
zaki et al., 2006). Termed b-cell desensitization, this decrease
in insulin secretion correlates with degranulation of the b cell
and can be reversed upon removal of the stimulant (Rustenbecket al., 2004). Nonetheless, in patients with type 2 diabetes, the
long-term hyperglycemic environment imposes irreversible
b-cell damage (glucose toxicity) that cannot be overcome
without medical intervention.
The ubiquitin ligase COP1 was initially identified in plants as
an essential negative regulator of light-mediated plant develop-
ment (Lau and Deng, 2012). Thus, when plants are grown in the
dark, COP1 represses photomorphogenesis by ubiquitylating
bZIP transcription factors driving the photomorphogenic pro-
gram and this targets them for proteasomal degradation.
Following exposure to light, COP1 activity is excluded from
the nucleus and its transcription factor substrates are stabilized,
allowing for the transcription of light-inducible genes. Remark-
ably, a majority of all light-controlled genes, representing greater
than 20% of the plant genome, are influenced by COP1 (Ma
et al., 2002).
COP1 also exists in a multi-subunit ubiquitin ligase in mam-
mals. Reported substrates include c-JUN, ETV1, c/EBPa,
acetyl-coenzyme A carboxylase, and CREB-regulated tran-
scription co-activator 2 (CRTC2) (Dentin et al., 2007; Marine,
2012; Qi et al., 2006). Studies of COP1-deficient mice indicated
a role for COP1 in tumor suppression (Vitari et al., 2011; Miglior-
ini et al., 2011). For example, COP1 deletion in prostate epithe-
lium stabilized the transcription factors cJUN, ETV1, and ETV4
and led to the development of prostate intraepithelial neoplasia
(Vitari et al., 2011). ETV1, ETV4, and ETV5 belong to the Pea3
group of the ETS family of transcription factors. Activated down-
stream of receptor tyrosine kinases, Pea3 transcription factors
regulate cell-type specific gene programs involved in cell differ-
entiation, signaling, and tissue morphogenesis (Lu et al., 2009;
Mao et al., 2009; Zhang et al., 2009). A recent study of ETV5-
deficient mice implicated ETV5 in glucose metabolism (Gutier-
rez-Aguilar et al., 2014). Interestingly, genome-wide association
studies (GWASs) have linked ETV5 and obesity (Welter et al.,
2014).
Here we identify a function for COP1 in regulating b-cell insulin
secretion. Deletion of COP1 from adult mouse b cells caused the
accumulation of Pea3 transcription factors and this activated
genes inhibitory to insulin secretion. b-cell defects associated
with COP1 loss could be ameliorated by the deletion of ETV1,
ETV4, and ETV5. Identification of the b-cell genes regulated byCell 163, 1457–1467, December 3, 2015 ª2015 Elsevier Inc. 1457
AB
G
D F
E
H I
C
Figure 1. Loss of COP1 in Adult b Cells Promotes Hyperglycemia in Mice
(A) Schematic shows the Cop1D1/+ allele with a lacZ reporter gene. NLS, nuclear localization sequence.
(B) Detection of b-galactosidase enzymatic activity (blue) in Cop1+/+ and Cop1D1/+ adult pancreas is shown. Black bar, 50 mm.
(C) Detection of b-galactosidase enzymatic activity (blue) and immunofluorescence staining of insulin (red, arrow) and glucagon (green, arrowhead) in aCop1D1/+
islet are shown. White bar, 50 mm.
(D) Schematic for Cop1 deletion in b cells (DCop1b). Cop1fl/fl Pdx1.CreERT2 mice were dosed at 8 weeks of age.
(E) Immunoblot for COP1 in control (Pdx1.CreERT2) and DCop1b islets is shown.
(F) COP1 protein expression in control and DCop1b islets was detected by immunohistochemistry. Black bar, 50 mm.
(G) Fasting blood glucose levels. Each symbol represents one mouse. Black line indicates the mean. Dashed lines mark 60 and 120 mg/dl.
(H) Intraperitoneal glucose tolerance tests (GTTs) of normoglycemic mice at 36 weeks post-tamoxifen are shown.
(I) Insulin tolerance tests of hyperglycemic DCop1b and control mice are shown.
Data are represented as mean ± SEM (*p < 0.05, **p < 0.005, and ***p < 0.0005 by unpaired Student’s t test). Analyses in (E) and (F) used mice at 3 weeks post-
tamoxifen. See also Figure S1.ETV1, ETV4, and ETV5 revealed a significant enrichment of dia-
betes and obesity-associated genes and included genes
involved in insulin granule docking. In normal b cells, ETV4 was
stabilized upon membrane depolarization and limited insulin
release under hyperglycemic conditions. Therefore, this study
identifies a requirement for COP1 and ETV transcription factors
in b-cell insulin secretion, and it illuminates an inhibitory mecha-
nism that can be activated in situations of increased secretory
demand.
RESULTS
Deletion of COP1 in Adult bCells Causes Hyperglycemia
in Mice
Cop1D1/+ mice (Vitari et al., 2011) with a lacZ reporter gene re-
placing exon 1 of one Cop1 allele (Figure 1A) revealed Cop1 to
be highly expressed in adult pancreatic islets (Figure 1B).
b-galactosidase activity was detected in both insulin-producing
b cells and glucagon-producing a cells (Figure 1C). To deter-
mine the role of COP1 in adult b cells, mice bearing conditional
alleles of Cop1 (Cop1fl/fl) (Vitari et al., 2011) and a
Pdx1.CreERT2 transgene (Gu et al., 2002) were dosed with
tamoxifen at 8 weeks of age to inactivate Cop1 in adult b cells1458 Cell 163, 1457–1467, December 3, 2015 ª2015 Elsevier Inc.(hereafter referred to as DCop1b mice, Figure 1D). Three
weeks after dosing, islets from DCop1b mice contained mark-
edly less COP1 protein than islets from Cop1+/+
Pdx1.CreERT2+ control mice (Figures 1E and 1F). Importantly,
no recombination was detected in the brain (Figure S1A) as has
been reported for some loci using Pdx1 drivers (Magnuson and
Osipovich, 2013).
Blood glucose levels in DCop1b mice fasted for 15–18 hr re-
mained within the normal range of 60–120 mg/dl for up to
8 weeks following tamoxifen treatment, but thereafter fasted
and randomly fed blood glucose levels were elevated in a subset
of the mice (Figure 1G; Figure S1B). After 36–40 weeks, 37% of
DCop1b mice had elevated glucose levels compared to 0% of
controls (Figure 1G). DCop1b animals that remained normogly-
cemic were severely glucose intolerant (Figure 1H). Glycemic
variability in DCop1b animals was not due to differences in
Cop1fl/fl recombination because normoglycemic DCop1b mice
had comparable levels of COP1 compared to hyperglycemic an-
imals (Figures S1C and S1D). Further, body weights of DCOP1b
mice after 36 weeks were comparable to those of controls (Fig-
ure S1E) and they exhibited normal insulin tolerance (Figure 1I),
thereby ruling out insulin insensitivity as a cause of hyperglyce-
mia in DCOP1b animals.
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Figure 2. Deletion of COP1 Results in
Glucose Intolerance and Decreased Insulin
Secretion
(A) Intraperitoneal GTTs are shown.
(B) Quantification of area under the curve (AUC) for
individual GTTs. Black line indicates the mean.
(C) In vivo glucose-stimulated insulin secretion
(GSIS) is shown.
(D) Plasma insulin levels upon hyperglycemic
clamping are shown.
Data are represented as mean ± SEM (*p < 0.05,
**p < 0.005, and ***p < 0.0005 by unpaired
Student’s t test). Analyses used mice at 3 weeks
post-tamoxifen with fasting blood glucose levels
between 60 and 120 mg/dl. See also Figures S2,
S3, and S4.COP1 Is Required for Glucose-Stimulated Insulin
Secretion
Given that the hyperglycemia seen in DCop1bmice was not due
to insulin insensitivity, we looked for defects in b-cell function
and/or maintenance. DCop1b mice exhibited defects in glucose
clearance as early as 3 weeks after tamoxifen treatment as
measured by intraperitoneal and oral glucose tolerance tests
(GTTs) (Figures 2A and 2B; Figure S2A). Importantly, glucose
intolerance was not seen in Cop1fl/fl Pdx1.CreERT2+ mice not
treated with tamoxifen (Figure S2B). The inability of DCop1b
mice toclearbloodglucoseasefficiently ascontrolswasaconse-
quence of decreased glucose-stimulated insulin secretion (GSIS;
Figure 2C). Whereas control animals exhibited an initial burst of
insulin secretion within 5 min of glucose challenge (the expected
first-phase response) followed by a more sustained period of in-
sulin secretion (the second-phase response), DCop1b mice
lacked a first-phase response and their second-phase response
was attenuated. DCop1b mice also exhibited defective insulin
secretion after blood glucose levels were clamped at 250 mg/dl
(Figures S2C–S2E). Basal plasma insulin levels did not differ be-
tweenDCop1bandcontrolmice, but, uponglucose infusion, con-
trol animals showed a 4-fold increase in plasma insulin whereas
DCop1b animals averaged less than a 2-fold increase (Figure 2D).
Decreased insulin secretion could reflect changes in b-cell
mass, differentiation state, and/or defects in insulin production
or processing (Kitamura, 2013; Orci et al., 1985; Talchai et al.,
2012). The DCop1b pancreas contained normal numbers of is-
lets that resembled control islets in terms of their size and
expression of genes associated with mature b cells (Figures
S3A–S3L). The amount of insulin and its cellular distribution in
DCOP1b islets was also equivalent to that seen in control islets
(Figures S4A–S4G). These observations suggested that COP1
deficiency might impact GSIS directly.Cell 163, 1457–1467, DCOP1 Deletion Results in Impaired
Insulin Granule Docking and
Exocytosis
b-cell GSIS is activated following the
Glut2-dependent import of glucose,
whereupon it is metabolized and intracel-
lular ATP is increased. KATP channel
closure causes membrane depolarizationand induces Ca2+ influx, which ultimately activates insulin
secretory vesicles for release (Rorsman and Braun, 2013; Fig-
ure 3A). The absence of first-phase insulin secretion in DCop1b
mice (Figure 2C) suggested a failure to release the pre-formed
insulin granules that are located close to the plasma mem-
brane (Seino et al., 2011). Consistent with this notion, the
membrane-depolarizing agents KCl and arginine triggered
significantly less insulin secretion from DCop1b islets than
from control islets (Figure 3B). Islet perifusion to measure dy-
namic insulin secretion (Figure 3C) corroborated this defect
because DCop1b islets released very little insulin when
exposed to high glucose or KCl compared to controls (Fig-
ure 3D). Ca2+ influx subsequent to membrane depolarization
was normal in DCop1b islets (Figure 3E), suggesting that the
secretion defect might be due to a problem with the insulin
granules themselves.
We tested if the failure to release pre-formed insulin granules
(the first-phase response) in DCop1b islets could be amelio-
rated with the incretin mimetic and GSIS agonist Exendin-4
(Drucker and Nauck, 2006). Activation of incretin receptors
GIP and GLP-1 increases cAMP, which activates both PKA-
dependent and -independent mechanisms to prime insulin
vesicles for release (Seino and Shibasaki, 2005; Seino et al.,
2011; Song et al., 2011). This priming step potentiates the first
phase of insulin secretion in response to glucose. As expected,
Exendin-4 pretreatment (Figure 3F) enhanced GSIS in control
animals (Figure 3G) and improved glucose tolerance (Fig-
ure 3H). The DCOP1b mice also responded to Exendin-4
with increased GSIS (Figure 3G) and this normalized glucose
tolerance to control levels (Figure 3H; compare red and black
solid lines). Direct activation of either PKA or the guanine
nucleotide exchange factor Epac, components downstream
of incretin signaling, also potentiated insulin exocytosis inecember 3, 2015 ª2015 Elsevier Inc. 1459
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Figure 3. COP1 Functions in GSIS
(A) Schematic shows GSIS.
(B) Insulin secretion from islets incubated in vitro with the stimuli indicated for 1 hr at 37C is shown.
(C) Schematic of islet perifusion setup as previously described (Kaihara et al., 2013). Islets (125 per animal) were perifused with various secretogogues: basal
glucose (2.8 mM), high glucose (16.6 mM), or 30 mM KCl.
(D) Dynamic insulin secretion of islets in the perifusion chamber is shown. Error bars, SEM.
(E) Fura-2 imaging of calcium flux in islets is shown. ROI, region of interest.
Data are represented as mean ± SEM (*p < 0.05 by unpaired Student’s t test). Analyses used mice at 3 weeks post-tamoxifen.
(F) Schematic shows Exendin-4 treatment prior to GSIS assay.
(G) Intraperitoneal GTTs are shown.
(H) In vivo GSIS.
(I) Electron micrographs of b cells. White dotted line outlines plasma membrane. Scale bars, 0.2 mm.
Analyses used mice at 3 weeks post-tamoxifen with fasting blood glucose levels between 60 and 120 mg/dl. See also Figure S5.DCop1b islets (Figure S5A). These data indicate that DCop1b
insulin granules can be released if the exocytosis defect
caused by COP1 deficiency is bypassed by activation of the
incretin pathway.
The first-phase insulin response releases insulin granules
already docked at the plasma membrane (Rorsman and Re-
nstro¨m, 2003). To determine if DCop1 b cells had fewer
docked granules, we performed morphometric analyses on1460 Cell 163, 1457–1467, December 3, 2015 ª2015 Elsevier Inc.electron micrographs of islets. In comparison to control b
cells, DCOP1 b cells had fewer docked granules, defined as
having cores between 0 and 100 nm from the plasma mem-
brane (Figures 3I, 5B, and 5C). These results, along with the
finding that first-phase insulin secretion is absent in DCOP1b
animals, are consistent with a function for COP1 in the dock-
ing of insulin secretory granules necessary for glucose-stimu-
lated release.
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Figure 4. ETV Transcription Factors Are the Critical Substrates for COP1 in b Cells
(A, C, E, and H) Immunoblots of ETV1, ETV4, and ETV5 in islets are shown.
(B and J) Intraperitoneal GTT AUC was calculated for each individual animal and grouped by genotype.
(D, F, G, and I) GTTs on the genotypes indicated are shown.
For AUC box and whisker graphs, error bars indicate the range. Box represents 25th–75th percentile with line at median value (*p < 0.05, **p < 0.005, ***p < 0.0005,
and ****p < 0.00005 by unpaired Student’s t test). Analyses usedmice at 3 weeks post-tamoxifen with fasting blood glucose levels between 60 and 120mg/dl. See
also Figure S6.Pea3 Transcription Factors Are the Critical COP1
Substrates in Pancreatic b Cells
To better understand the insulin secretion defect in DCop1b
mice, we determined the critical substrates of COP1 in b cells.
Several proteins are ubiquitylated and targeted for proteasomal
degradation by COP1 (Marine, 2012), including ETV1, ETV4,
and ETV5. ETV4 and ETV5 proteins (Figure 4A), but not mRNAs
(Figures S6A and S6B), were more abundant in DCop1b islets
than in control islets, which is consistent with post-transcrip-
tional regulation of ETV4 and ETV5 by COP1 in b cells. ETV1,
however, was not elevated significantly in DCop1b islets (Fig-
ure 4H). We tested whether increased ETV4 and ETV5 were
responsible for the insulin secretion defect in DCop1b mice by
introducing Etv4ko mutant and/or conditional Etv5fl alleles(Zhang et al., 2009). The mutant Etv4 and Etv5 alleles were on
a mixed genetic background, which itself did not alter the
glucose intolerance of the DCop1b mice (Figure 4B, compare
white versus red bars), which originally had an inbred
C57BL/6 background (Figure 2A).
The DCop1b Etv4ko/+ Etv5fl/+ mice still expressed more ETV4
and ETV5 proteins in their islets than control mice (Figure 4C)
and were glucose intolerant (Figures 4B and 4D), but DCop1b
Etv4ko/+ Etv5fl/fl mice showed less severe glucose intolerance
thanDCop1bmice (Figures 4B, 4E, and 4F). Elimination of the re-
maining Etv4 wild-type allele did not further ameliorate the
glucose intolerance. Indeed, DCop1b Etv4ko/ko Etv5fl/fl mice
were indistinguishable from DCop1b mice (Figures 4B and 4G).
Immunoblotting revealed that ETV1 was abnormally high inCell 163, 1457–1467, December 3, 2015 ª2015 Elsevier Inc. 1461
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Figure 5. Etv Mutations Rescue Insulin Secretion and Granule
Docking Defects Caused by COP1 Deficiency
(A) Insulin secretion from islets incubated in vitro with the stimuli indicated for
1 hr at 37C is shown.
(B) Electron micrographs of b cells. White dotted line outlines plasma mem-
brane. DCop1b; DEtvb, DCop1b Etv1fl/fl Etv4ko/ko Etv5fl/fl. Scale bars, 0.2 mm.
(C) Quantification of docked insulin granules. The distance from the granule
center to the plasma membrane was binned into two groups. Data are pre-
sented as percentage granule density relative to cytoplasmic density (average
granule density in cytoplasm equals 100%) (Gomi et al., 2005).
Analyses used mice at 3 weeks post-tamoxifen with fasting blood glucose
levels between 60 and 120 mg/dl. Data are represented as mean ± SEM (*p <
0.05 and ***p < 0.0005 by unpaired Student’s t test).DCop1b Etv4ko/ko Etv5fl/fl islets (Figure 4H), perhaps reflecting
compensatory mechanisms triggered by the loss of ETV4 and
ETV5. Strikingly, DCop1b Etv1fl/fl Etv4ko/ko Etv5fl/fl mice lacking
all three ETV transcription factors in b cells did not exhibit the
glucose intolerance seen in DCOP1b mice (Figures 4I and 4J).
Cop1fl/+ Etv1fl/fl Etv4ko/ko Etv5fl/fl Pdx1.CreERT2+ mice resem-
bled controls in GTTs (Figure 4J), indicating that ETV deficiency
does not improve glucose tolerance when COP1 is present.
Consistent with rescue of the glucose intolerance phenotype,
islets fromDCop1b Etv1fl/fl Etv4ko/ko Etv5fl/flmice secreted insulin1462 Cell 163, 1457–1467, December 3, 2015 ª2015 Elsevier Inc.in response to KCl in vitro similar to control islets (Figure 5A). In
addition, the decrease in docked insulin granules observed in the
DCop1b pancreas was not seen in the DCop1b Etv1fl/fl Etv4ko/ko
Etv5fl/fl pancreas (Figures 5B and 5C). Collectively, these data
indicate that elevated ETV1, ETV4, and ETV5 caused by COP1
deficiency in b cells impaired insulin secretion and drove glucose
intolerance.
Identification and Functional Analysis of Pea3-
Dependent Genes in b Cells
RNAsequencingofcontrol,DCop1b, andDCop1bEtv1fl/flEtv4ko/ko
Etv5fl/fl islets identified genes that were dysregulated in DCop1b
islets as a result of increased ETV1, ETV4, and ETV5 (Figure 6A;
GEO: GSE70788). Of the genes that were dysregulated in
DCop1b islets, 77% approached expression levels seen in con-
trols upon concomitant deletion of ETV1, ETV4, and ETV5 (Fig-
ure 6B; Table S1). Genetic variants associated with diabetes
risk, identified from the National Human Genome Research Insti-
tute (NHGRI) GWAS catalog (Welter et al., 2014), were signifi-
cantly enriched among these ETV-dependent genes (25/483
genes) (Figure 6C; Table S2). In contrast, COP1-dependent
genes not rescued by ETV deletion were not significantly repre-
sented (2/170 genes). Further, given the known association be-
tween ETV5 and obesity (Welter et al., 2014), analysis of genetic
variants associated with obesity showed significant representa-
tion among ETV-dependent genes (13/483 genes) (Figure 6C;
Table S3).
Two ETV-dependent genes (Figures 6A and 6B; Figure S7A)
stood out because of their potential involvement in granule
docking: Exocyst-6 (Exoc6) and Synaptotagmin-like 3 (Sytl3).
EXOC6 is a known component of the Exocyst complex that
docks insulin granules to the plasma membrane (Saito et al.,
2008; Tsuboi et al., 2005; Xie et al., 2013). SYTL3 has been
shown to bind to Rab27A (Fukuda, 2013; Wang et al., 2013),
a small GTPase that mediates insulin granule docking (Kasai
et al., 2005). The qRT-PCR confirmed that these genes were
upregulated in an ETV-dependent manner in DCop1b islets
(Figures 6D and 6E). To determine if these genes were direct
targets of ETV1, ETV4, or ETV5, we looked for potential
ETV-binding motifs within their promoters. Sequences fitting
the consensus ETV core binding motif G(C/A)GGA(A/T)(G/A)
were identified (Figures S7C and S7D) and their deletion or
mutation compromised the ability of the promoter sequences
to drive ETV5-dependent expression of a luciferase reporter
gene (Figures S7E and S7F). These data are consistent with
Exoc6 and Sytl3 being direct transcriptional targets of the
ETVs.
To directly determine if EXOC6 and SYTL3 impact insulin
secretion, we overexpressed them in mouse insulinoma
btc6 cells that secrete insulin constitutively. In contrast to
ectopic ETV5, which decreased insulin secretion from bTC6
cells, overexpression of either EXOC6 or SYTL3 alone did
not result in a statistically significant reduction in insulin
secretion (Figure 6F). Co-expression of EXOC6 and SYTL3,
however, did cause a significant reduction in insulin secretion
(Figure 6F). These results suggest that expression of Exoc6
and Sytl3 by ETV transcription factors is inhibitory to insulin
secretion.
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Figure 6. Expression of ETV Target Genes Exoc6 and Sytl3 Correlate with Decreased Insulin Secretion
(A) RNA sequencing strategy to identify ETV-dependent genes in adult DCop1b islets is shown.
(B) Percentages of genes dysregulated in DCop1b islets that were normalized in the absence of ETV1, ETV4, and ETV5 are shown.
(C) Venn diagram represents the overlap among ETV-regulated, diabetes GWAS, and obesity GWAS genes.
(D and E) Expressions of Exoc6 (d) and Sytl3 (e) in islets are shown.
(F) Insulin secretion from transfected btc6 cells is shown.
Data are represented asmean ± SEM (*p < 0.05 and ***p < 0.0005 by unpaired Student’s t test). Analyses usedmice at 3 weeks post-tamoxifen with fasting blood
glucose levels between 60 and 120 mg/dl. See also Figure S7 and Tables S1, S2, and S3.ETV4 Inhibits Insulin Secretion after Prolonged Glucose
Stimulation
Given that a significant subset of ETV-dependent genes was en-
riched in diabetes-associated genes, ETV transcription factors
also may function in normal glucose homeostasis. Interestingly,
normal b cells expressed a lot more ETV4 protein after stimula-
tion with the depolarizing agent potassium chloride for 20 min
(Figure 7A). Etv4mRNA abundance was unchanged (Figure 7A),
indicating that a post-translational mechanism was responsible
for the increase in ETV4 protein. ERK inhibition suppressed the
increase in ETV4 protein (Figure 7A), which is consistent with
previous studies identifying ETS proteins as effectors of the
MEK/ERK MAPK pathway (Yordy and Muise-Helmericks,
2000). To investigate whether ETV4 serves to inhibit insulin
secretion after membrane depolarization, we compared the in-
sulin secretory response of ETV4-deficient islets with that of con-
trol islets after incubation in high glucose for 16 hr (Figure 7B).
Potential compensatory changes in ETV1 and ETV5 abundance
due to ETV4 loss were avoided by using islets isolated from
tamoxifen-treated Etv1fl/fl Etv4ko/ko Etv5fl/fl Pdx1.CreERT2+
(DETVb) and Etv1fl/fl Etv4ko/+ Etv5fl/fl Pdx1.CreERT2+ (control) lit-
termates. Consistent with the literature (Yamazaki et al., 2006),
control islets exhibited attenuated GSIS after incubation in
10 mM compared to 5 mM glucose (Figure 7C, black bars). Incontrast, DETVb islets showed an equivalent GSIS whether incu-
bated in 5 or 10 mM glucose (Figure 7C, blue bars). Indeed,
DETVb islets exhibited increased insulin secretion in 10 mM
glucose when compared to controls (Figure 7C, black versus
blue bars). These results indicate that ETV4 inhibits insulin secre-
tion after prolonged glucose stimulation (Figure 7D).
DISCUSSION
In this study, we identified a requirement for COP1, an E3 ligase
that regulates the transcription factors ETV1, ETV4, and ETV5, in
adult b-cell maintenance. In the absence of COP1, mice devel-
oped elevated fasting glycemia due to impaired insulin secretion.
The hyperglycemia seen upon COP1 deletion was not driven by
peripheral insulin resistance, but rather by impaired GSIS in b
cells. The variability in hyperglycemic onset within the DCOP1b
cohort probably represents the ability of individual mice to
compensate for their impaired secretory response. Over time,
similar to type 2 diabetic patients (Weir and Bonner-Weir,
2004), some animals must fail to keep up with the increased in-
sulin secretory demand and reach thresholds of cellular exhaus-
tion and glucose toxicity, leading to chronic hyperglycemia.
Consistent with this notion, islets isolated from 10-month-old hy-
perglycemic DCOP1b animals exhibited increased endoplasmicCell 163, 1457–1467, December 3, 2015 ª2015 Elsevier Inc. 1463
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Figure 7. High Glucose-Dependent GSIS
Attenuation Is Dependent on ETV4
(A) Pan-ETV immunoblot of islet lysates treated
with 11.8 mM glucose/RPMI/FBS ± 30 mM KCl
with or without ERK inhibitor for 20 min. ETV4
mRNA levels are indicated for each stimulation.
(B) Schematic shows the varied glucose treatment
on isolated islets prior to GSIS.
(C) In vitro GSIS from islets islolated from animals
3 weeks post-tamoxifen is shown.
Data are represented as mean ± SEM (*p < 0.05 by
unpaired Student’s t test).
(D) Model for COP1 and ETV function during GSIS
in adult b cells. Membrane depolarization during
GSIS pathway activation stabilizes ETV transcrip-
tion factors. Accumulation of ETV protein levels
activates genes that are inhibitory to insulin granule
exocytosis.reticulum (ER) stress, which is commonly associated with
glucose toxicity (Back and Kaufman, 2012; Figure S1F).
The glucose intolerance caused by COP1 deletion was a
consequence of diminished GSIS. We narrowed the phenotype
to abnormalities with the insulin granule pool, because mem-
brane depolarization using KCl and arginine failed to elicit a
secretory response despite normal calcium signaling. The
DCop1b islets had a paucity of granules docked at the plasma
membrane for the first phase of insulin secretion (Gaisano,
2014). Exendin-4 or activators of the incretin pathway stimulated
the glucose-mediated release of DCop1b insulin granules,
perhaps reflecting the ability of PKA to recruit new granules to
the plasma membrane (Seino et al., 2011). Regardless, these
data highlighted that the insulin granules in DCop1b islets were
inherently functional for exocytosis.
Insulin secretion involves the transport, docking, and fusion of
insulin granules to the plasmamembrane, a process that is regu-
lated by conserved protein families, such as Rab GTPases, and
solubleN-ethylmaleimide-sensitive factor attachment protein re-
ceptors (SNAREs) (Wang and Thurmond, 2009). We identified
two genes dysregulated upon deletion COP1, Exoc6 and Sytl3,
whose functions were previously uncharacterized in b cells but
have been known to include interaction with components of
the insulin secretory machinery. EXOC6 (also known as yeast
SEC15) is part of the mammalian SEC6-SEC8 exocyst complex,
which has been shown to function in insulin granule docking and
secretion (Saito et al., 2008; Tsuboi et al., 2005; Xie et al., 2013).
Truncations in components of this complex decrease the supply1464 Cell 163, 1457–1467, December 3, 2015 ª2015 Elsevier Inc.of insulin granules close to the plasma
membrane, possibly by functioning in
the conversion of reserve granules to the
readily releasable pool (Tsuboi et al.,
2005). We found that expression of the
calcium-sensitive Rab27a-binding pro-
tein Sytl3 also was increased in DCop1b
islets, which may further contribute to
the impairment in vesicle docking (Fu-
kuda, 2002; Fukuda et al., 2002; Kurow-
ska et al., 2012). The small monomericGTPase Rab27a also is required for the release and replenish-
ment of docked granules during GSIS (Kasai et al., 2005). We hy-
pothesize that a subset of ETV-dependent genes, including
Exoc6 and Sytl3, act in concert to modulate the insulin secretory
defect in DCop1b islets. In support of this, expression of either
Exoc6 or Sytl3 had no effect on insulin secretion, but expression
of both genes significantly attenuated insulin secretion in bTC6
cells.
We identified Pea3 transcription factors as the critical COP1
substrates in pancreatic b cells. The accumulation of ETV4 and
ETV5 caused the phenotypes found after deletion of COP1 in b
cells. However, deletion of ETV4 and ETV5 alone was not suffi-
cient to normalize the phenotypes seen inDCop1bmice because
of an unexpected compensatory increase in ETV1. Conse-
quently, it is only upon deletion of all three Pea3 family members,
ETV1, ETV4, and ETV5, that phenotypes arising fromCOP1 dele-
tion were fully reversed. Of the b-cell-specific ETV-dependent
genes identified, there was significant enrichment of diabetes
and obesity-associated genes, including Exoc6. ETV5 itself has
been linked in GWASs to obesity and previous studies have re-
vealed that whole-body Etv5 knockout mice are leaner and
have reduced body weight compared to control animals (Gutier-
rez-Aguilar et al., 2014). It would be interesting to determine if the
ETV-dependent genes we identified are direct targets of ETV5 in
obesity models and whether they function in regulating BMI and/
or energy expenditure.
While we have uncovered a mechanism by which insulin
secretion can be suppressed through the accumulation of ETV
transcription factors and their gene targets, when is this regula-
tory mechanism important? We believe that it represents an
important feedback mechanism in b cells following sustained
exposure to membrane-depolarizing secretagogues, including
high potassium and high glucose. This mechanism would pre-
vent unabated insulin release and the exhaustion of insulin re-
serves. Others have shown that modest but sustained exposure
of b cells to elevated potassium and glucose results in a desen-
sitization phenomenon and a dose-dependent decrement in in-
sulin secretion (Yamazaki et al., 2006). However, the molecular
mechanism underlying this phenomenon was unclear. We
show that ETV4 protein abundance increased in islets cultured
with potassium chloride and, consistent with a role for ETV4 in
desensitization, high glucose attenuated insulin release from
control islets, but not ETV4-deficient islets. This attenuation,
which at late stages is classically attributed to degranulation of
the b cell, may reflect an intrinsic mechanism to dampen insulin
secretion to prevent cellular stress and/or insulin exhaustion
(Figure 7D). In keeping with this notion, Etv4ko/ko Etv5fl/fl
Pdx1.Cre animals show partial resistance to high-fat diet (data
not shown), though non-b-cell effects cannot be ruled out due
to the systemic deletion of ETV4. Future studies will clarify the
b-cell-specific role of ETV transcription factors in high-fat diet
models and other situations of increased insulin secretory de-
mand and b-cell exhaustion.
EXPERIMENTAL PROCEDURES
Generation of Mice
Cop1D1/+, Cop1fl/fl, Etv4ko/ko, Etv5fl/fl, Etv1fl/fl, and Pdx1.CreERT2 mice were
described previously (Gu et al., 2002; Patel et al., 2003; Vitari et al., 2011;
Zhang et al., 2009). CreERT2 was activated in mice by intraperitoneal injec-
tions of 100 mg/kg tamoxifen dissolved in sunflower seed oil (Sigma) for 5
consecutive days. The Genentech Institutional Animal Care and Use Commit-
tee approved all protocols.
Genotyping
Cop1 exon 1 primers 50-GCTACCATTACCAGTTGGTCTGGTGTC-30, 50-CC
AACCCCACAAGTTCAGGGAT-30, and 50-CTGCATCATGTTGTGTGATTGC
AT-30 yield 873-bp wild-type and 532-bp knockout DNA fragments. Cop1
exon 3 primers 50-CATTGAAATGATAATTGCAGATTTGGTC-30, 50-CACCAC
CCTGCCAGATCTTAAATATAGAT-30, and 50-CAAACCTGTCACAAAATACTAT
TGTGCTCTC-30 yield 686-bp wild-type, 753-bp floxed, and 452-bp knockout
DNA fragments. Cre-specific primers 50-GCTAAACATGCTTCATCGTCGG
TC-30 and 50-CCAGACCAGGCCAGGTATCTCTG-30 amplified a 582-bp
fragment.
Histology and Immunohistochemistry
Whole pancreas was fixed in 4% paraformaldehyde for immunofluorescence
staining or 20% Formalin for staining with H&E. b-galactosidase enzymatic ac-
tivity was revealed by incubating 10-mm pancreatic sections with 0.5 mg/ml
5-bromo-4-chloro-3-indolyl-b-d-galactopyranoside (Sigma B4252) overnight
at 37C. Sections were counterstained with Nuclear Fast Red (ENG Scientific
9040). When combined with immunofluorescence staining, sections were
blocked with 10% normal rabbit serum and 10% normal goat serum for
30 min, and then stained with primary antibodies for 1 hr at room temperature.
Slides were washed three times for 5 min each then incubated for 1 hr with
Alexa-Fluor conjugated secondary antibodies (Jackson Laboratory) at room
temperature. Slides were mounted with Prolong Gold (Invitrogen P36934). Im-
aging was performed using the Nuance Multi-spectral Imaging System
(Caliper Life Sciences).
COP1 immunohistochemistry was performed on a Dako automated staining
platform. Heat-induced epitope retrieval (Dako) was used for both glucagon
and COP1 immunohistochemistry. Biotinylated goat anti-guinea pig IgG andgoat anti-rabbit IgG were used for detection of anti-insulin and anti-glucagon
antibodies in combination with ABC peroxidase Elite detection (Vector Labo-
ratories) and DAB chromogen. Biotinylated goat anti-hamster followed by
Streptavidin-horseradish peroxidase with tyramide signal amplification (Perki-
nElmer) and DAB chromogen were used to detect anti-COP1 antibodies. All
sections were counterstained with Mayer’s hematoxylin. Primary antibodies
usedwere as follows: guinea pig anti-insulin (Dako A056401-2, 5.5 mg/ml), rab-
bit anti-glucagon (Cell Signaling Technology 2760, 0.04 mg/ml), mouse pro-in-
sulin (Developmental Studies Hybridoma Bank [DSHB] GS-9A8), and hamster
monoclonal anti-COP1 antibody (Genentech IDIO.10.4.4.1, 0.12 mg/ml).
In Vivo GTTs and GSIS Assays
Mice fasted 15–18 hr were injected intraperitoneally with 2 mg glucose/g body
weight or given 1 mg glucose/g body weight orally. Blood samples were taken
by tail vein nick for glucose measurement (FreeStyle Lite glucometer) and
serum collection. Treatment with Exendin-4 (5 mg/kg body weight) was con-
ducted 15 min prior to injection of 2 mg/kg glucose. Serum insulin was
measured by ELISA (Alpco).
Hyperglycemic Clamping
Hyperglycemic clamping of mice was conducted at the Vanderbilt University
Mouse Metabolic Phenotyping Center as previously described (Berglund
et al., 2008).
Islet Harvest and Secretogogue Assays
Islets were harvested from mice 3 weeks post-tamoxifen by collagenase
digestion, histopaque density centrifugation (Sigma 11191), and hand picking
(Kaihara et al., 2013). After overnight recovery in RPMI medium containing
11.8 mM glucose, 10% FBS, 50 U/ml penicillin, and 50 mg/ml streptomycin,
ten islets per mouse were transferred into Kreb’s buffer containing 2.8 mM
glucose for 1 hr to measure basal insulin secretion. After supernatant removal,
secretogogues (16.8 mM glucose, 30 mM KCl in 2.8 mM glucose or 20 mM
arginine in 2.8 mM glucose) in Kreb’s buffer were added to the islets for 1 hr.
For experiments requiring activator pretreatment, 100 nM Exendin-4 (Sigma
e7144), 10 mM Forskolin (R&D Systems 1099), 10 mM Epac activator 8-
pCPT-2-O-Me-cAMP-AM (R&D Systems 4853), and/or 10 mM PKA activator
N6-Benzoyladenosine-30,50-cyclic monophosphate (R&D Systems 5255) was
added 15 min prior to KCl stimulation. Insulin in the supernatants was
measured using Meso Scale Discovery (MSD) standard insulin assay. Results
are presented as total insulin secreted after normalization to basal secretion in
2.8 mM glucose. For measurements of insulin content, islets were lysed in ra-
dioimmunoprecipitation assay (RIPA) buffer and insulin content wasmeasured
using the MSD standard insulin assay. DNA and protein content in the same
lysates were measured to account for differences in islet size.
Islet Perifusion Assays
Islets from normoglycemic control and DCop1bmice were harvested 3 weeks
post-tamoxifen treatment. Harvested islets were incubated overnight in RPMI
containing 11.8 mM glucose, 10% FBS, 50 U/ml penicillin, and 50 mg/ml strep-
tomycin and then placed in a perifusion chamber as previously described (Kai-
hara et al., 2013). Flow rate of fluid input (2.8 mMglucose, 16.6 mM glucose, or
30 mM KCl in Kreb’s buffer) was 1 ml/min and fractions were collected every
minute. Graph represents three perifusions from three different mice per
group.
Calcium Imaging
As previously described (Kaihara et al., 2013), isolated islets were incubated
with 5 mM fura-2-AM (Invitrogen) in 2 mM glucose-Kreb’s buffer for 30 min. Im-
age measurements were acquired at 10-s intervals and data were expressed
as the fold change in the A340 nm/A380 nm ratio normalized to basal 2.8-mM
glucose readings.
Electron Microscopy and Morphometric Measurements
Samples were fixed in 1/2 Karnovsky’s fixative (2% paraformaldehyde and
2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer [pH 7.2]), post-fixed
in 1% aqueous osmium textroxide, and dehydrated through a series of ethanol
washes followed by two propylene oxide washes. Samples were embedded in
Eponate 12 (Ted Pella) and cured at 65C overnight. Semi-thin (300-nm) andCell 163, 1457–1467, December 3, 2015 ª2015 Elsevier Inc. 1465
ultrathin (80-nm) sections were obtained with an Ultracut microtome (Leica).
Semi-thin sections were stained with toluidine blue and examined by bright-
field microscopy to identify islets. Once islets were identified, parallel ultrathin
sections were prepared, counterstained with 1%uranyl acetate and 0.2% lead
citrate, and examined in a JEOL JEM-1400 transmission electron microscope
(TEM) at 120 kV. Images were captured with a GATAN Ultrascan 1000 CCD
camera. For immunogold labeling, samples were fixed in 4% paraformalde-
hyde and 0.2% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2). Samples
were washed, dehydrated, and infiltrated with LR White resin (London Resin).
Sample blocks were cured at 55C overnight. Ultrathin sections were labeled
with a polyclonal anti-insulin antibody (Dako), followed by biotinylated donkey
anti-guinea pig antibody (Jackson ImmunoResearch Laboratories) and strep-
tavidin conjugated with 15 nm colloidal gold particles (Electron Microscopy
Sciences). Labeled sections were counterstained with 2% uranyl acetate
and imaged as described above.
Morphometry
Dense core vesicle size distribution bar graphs are presented as dense core
vesicle size (circumference in pixels using ImageJ software) as a function of
percentage total vesicles. Circumferences of 80 vesicles were measured
from two animals per genotype.
Docked insulin granules were measured as described previously (Gomi
et al., 2005). Briefly, the distance from granule centers to the plasma mem-
brane was measured and then binned into two groups (0–100 nm and 100–
300 nm). The data are represented as percentage granule density (granules/
area) relative to cytoplasmic density (granule density in cytoplasm equals
100%).
qRT-PCR
Total cellular RNA was prepared using an RNeasy kit (QIAGEN) with on-col-
umn DNase treatment. RT-PCR reactions were performed in 384-well plates
on a 7900HT Fast Real-Time PCR System (Applied Biosystems). Taqman
gene expression assays (Applied Biosystems) were as follows: Pdx1,
mM00435565_m1; Nkx6.1, Mm00454961_m1; Neurod1, Mm01280117_m1;
Ngn3, Mm00437606_s1; Sox9, Mm00448840_m1; Hes1, Mm01342805_m1;
Nanog, Mm02384862_g1; Oct4, Mm03053917_g1; Sox2, Mm03053810_s1;
Ins1, Mm01950294_s1; Ins2, Mm00731595_gH; Exoc6, Mm00558419_m1;
and Sytl3, Mm00473333_m1.
Western Blots
Antibodies recognized b-actin (Novus Biologicals NB600-501); COP1 (Genen-
tech 28A4); ETV1, 4, or 5 (Genentech 20H5); ETV1 (Genentech 13G11); and
Exoc6 (Novus NBP1-85031). The islets (100) were lysed in 50 ml RIPA buffer
with 10% SDS, phosSTOP phosphatase, and protease inhibitors (Roche);
15 ml denatured lysate was run per sample.
Insulin Secretion in bTC6 Cells
Insulin secretion was measured 48 hr after btc6 cells were transfected using
Lipofectamine 3000 (Life Technologies). Total secreted insulin was measured
from supernatant collected after a 1-hr incubation in fresh medium (DMEM,
15% FBS, 50 U/ml penicillin, and 50 mg/ml streptomycin).
RNA Sequencing
RNA was extracted from adult islets using RNeasy kits (QIAGEN) with on-col-
umnDNase treatment. RNA (500 ng–1 mg) was submitted for analysis using the
Illumina HiSeq 2500 platform. Sequencing reads were aligned to the mouse
genome (NCBI37) with RefSeq gene models (RefSeq version 53, downloaded
on June 16, 2012) using GSNAP (version 2013-10-10) and the following param-
eters: -M 2 -n 10 -B 2 -i 1 -N 1 -w 200000 -E 1–pairmax-rna = 200000–clip-
overlap. Gene expression levels were computed by summing the number of
reads mapping to exons of RefSeq genes. Counts were normalized using
size factors (as described by DESeq2) to account for library size variation. Dif-
ferential expression between groups of samples was computed on the normal-
ized counts using the R DESeq2 package. Cop1-dependent genes were iden-
tified as genes differentially expressed between the control and DCop1b islets
(adjust p < 0.05, fold change > 1.5). From this list, ETV-dependent rescued
genes were identified as differentially expressed genes (in the same direction)
between DCop1b and DCop1b; DEtvb islets (adjusted p < 0.1).1466 Cell 163, 1457–1467, December 3, 2015 ª2015 Elsevier Inc.Diabetes and Obesity GWAS Analysis
GWAS data were obtained from the NHGRI GWAS catalog (Welter et al.,
2014; downloaded on December 19, 2014) using the following search
terms: diabetes, obesity, and BMI. A total of 468 diabetes- and 322
obesity-associated SNPs were identified. Genes reported or mapped by
the catalog to be associated with these SNPs were then mapped to their
mouse orthologs using the Ensembl Biomart orthology mapping (Biomart
version 77, October 2014). The overlap between ETV-dependent genes
and the GWAS diabetes/obesity gene sets was evaluated using a permuta-
tion test.ACCESSION NUMBERS
The accession number for the RNA sequencing reported in this paper is GEO:
GSE70788.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and three tables and can be
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